Caris Life Sciences (CAI) Non-Current Debt (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Non-Current Debt of $381.1 million for Q1 2026, up 0.59% quarter-over-quarter from $378.8 million in Q4 2025.
Caris Life Sciences (CAI) Non-Current Debt (2024 - 2026) Analysis & Trends
Caris Life Sciences' Non-Current Debt history runs 3 years deep, the most recent figure standing at $381.1 million for Q1 2026.
- In Q1 2026, Non-Current Debt changed N/A year-over-year to $381.1 million; the TTM figure through Mar 2026 stood at $381.1 million (changed N/A YoY), while the FY2025 annual figure was $378.8 million, up 1.52% from the prior year.
- Non-Current Debt for Q1 2026 stood at $381.1 million, up from $378.8 million in the prior quarter.
- The five-year high for Non-Current Debt was $381.1 million in Q1 2026, with the low at $373.1 million in Q4 2024.
- The 3-year median for Non-Current Debt is $375.9 million (2025), against an average of $376.5 million.
- Peak annual rise in Non-Current Debt reached 1.52% in 2025, while the deepest fall reached 1.52% in 2025.
- Caris Life Sciences' Non-Current Debt stood at $373.1 million in 2024, then climbed by 1.52% to $378.8 million in 2025, then gained by 0.59% to $381.1 million in 2026.
- Business Quant data shows CAI's Non-Current Debt at $381.1 million in Q1 2026, $378.8 million in Q4 2025, and $375.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | 392.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 392.97 Mn |
| Mar 31, 2026 | 381.07 Mn |
| Dec 31, 2025 | 378.82 Mn |
| Sep 30, 2025 | 375.88 Mn |
| Jun 30, 2025 | 373.42 Mn |
| Dec 31, 2024 | 373.14 Mn |